Citigroup
PCSA icon

Citigroup’s Processa Pharmaceuticals PCSA Stock Holding History

Citigroup’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35 Buy
+14
New +$38 ﹤0.01% 5668
2025
Q4 		– Sell
-1,362
Closed -$6.53K – 6355
2025
Q3 		$6.53K Buy
+1,362
New +$7.19K ﹤0.01% 5148

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citigroup's PCSA Position: Q1 2026 in Review

Citigroup opened a new position in Processa Pharmaceuticals (PCSA) in Q1 2026: 14 shares worth $35. The stake represents ﹤0.01% of the portfolio and ranks #5668 among its holdings. This is a return to the name: Citigroup previously reported a position in PCSA as recently as Q3 2025.

Citigroup first reported a position in PCSA in Q3 2025 and has held it in 2 quarters since. The position peaked at $6.53K in Q3 2025. 10 funds tracked by Wall St. Rank hold PCSA as of Q1 2026.

  • Citigroup held 14 shares of Processa Pharmaceuticals worth $35 as of Q1 2026.
  • Processa Pharmaceuticals was a new Citigroup position in Q1 2026.
  • Processa Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5668 holding.
  • Citigroup first reported a position in Processa Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Citigroup's Processa Pharmaceuticals position peaked at $6.53K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.